Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016 - GlobalData

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016 - GlobalData
Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016
Published Nov 01, 2016
131 pages — Published Nov 01, 2016
Price US$ 4,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's Medical Devices sector report, Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016' provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

- Extensive coverage of the Bioabsorbable Stents (BAS) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry

Reasons to buy

The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the products current stage of development, territory and estimated launch date

  
Source:
Document ID
GDME0235EPD
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
1 Table of Contents29
  1.1 List of Tables55
  1.2 List of Figures101
2 Introduction111
  2.1 Bioabsorbable Stents (BAS) Overview111
3 Products under Development125
  3.1 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development121
  3.2 Bioabsorbable Stents (BAS) - Pipeline Products by Territory131
  3.3 Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path141
  3.4 Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date151
  3.5 Bioabsorbable Stents (BAS) - Ongoing Clinical Trials161
4 Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies174
  4.1 Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development172
  4.2 Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development192
5 Bioabsorbable Stents (BAS) Companies and Product Overview2184
  5.1 Abbott Vascular Inc. Company Overview211
    5.1.1 Abbott Vascular Inc. Pipeline Products &Ongoing Clinical Trials Overview2124
  5.2 Amaranth Medical, Inc. Company Overview451
    5.2.1 Amaranth Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview459
  5.3 Arterius Ltd Company Overview541
    5.3.1 Arterius Ltd Pipeline Products &Ongoing Clinical Trials Overview541
  5.4 Biosten, LLC Company Overview551
    5.4.1 Biosten, LLC Pipeline Products &Ongoing Clinical Trials Overview551
  5.5 Biotronik SE &Co. KG Company Overview561
    5.5.1 Biotronik SE &Co. KG Pipeline Products &Ongoing Clinical Trials Overview566
  5.6 Boston Scientific Corporation Company Overview621
    5.6.1 Boston Scientific Corporation Pipeline Products &Ongoing Clinical Trials Overview625
  5.7 Cardionovum GmbH Company Overview671
    5.7.1 Cardionovum GmbH Pipeline Products &Ongoing Clinical Trials Overview673
  5.8 HangZhou HuaAn Biotechnology Co., Ltd. Company Overview701
    5.8.1 HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview701
  5.9 Icon Interventional Systems, Inc. Company Overview711
    5.9.1 Icon Interventional Systems, Inc. Pipeline Products &Ongoing Clinical Trials Overview711
  5.10 Japan Stent Technology Co., Ltd. Company Overview721
    5.10.1 Japan Stent Technology Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview721
  5.11 Kyoto Medical Planning Co., Ltd. Company Overview731
    5.11.1 Kyoto Medical Planning Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview731
  5.12 Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview741
    5.12.1 Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products &Ongoing Clinical Trials Overview741
  5.13 Medlogics Device Corporation Company Overview751
    5.13.1 Medlogics Device Corporation Pipeline Products &Ongoing Clinical Trials Overview751
  5.14 Meril Life Sciences Pvt. Ltd. Company Overview761
    5.14.1 Meril Life Sciences Pvt. Ltd. Pipeline Products &Ongoing Clinical Trials Overview763
  5.15 MicroPort Scientific Corporation Company Overview791
    5.15.1 MicroPort Scientific Corporation Pipeline Products &Ongoing Clinical Trials Overview792
  5.16 NanoCoeur, Inc. Company Overview811
    5.16.1 NanoCoeur, Inc. Pipeline Products &Ongoing Clinical Trials Overview811
  5.17 North Carolina State University Company Overview821
    5.17.1 North Carolina State University Pipeline Products &Ongoing Clinical Trials Overview821
  5.18 Northwestern University Company Overview831
    5.18.1 Northwestern University Pipeline Products &Ongoing Clinical Trials Overview832
  5.19 OrbusNeich Company Overview851
    5.19.1 OrbusNeich Pipeline Products &Ongoing Clinical Trials Overview852
  5.20 Pegasus Therapeutics, Llc Company Overview871
    5.20.1 Pegasus Therapeutics, Llc Pipeline Products &Ongoing Clinical Trials Overview871
  5.21 REVA Medical, Inc. Company Overview881
    5.21.1 REVA Medical, Inc. Pipeline Products &Ongoing Clinical Trials Overview886
  5.22 S3V Vascular Technologies Company Overview941
    5.22.1 S3V Vascular Technologies Pipeline Products &Ongoing Clinical Trials Overview941
  5.23 Shanghai MicroPort Medical Group Co Ltd Company Overview951
    5.23.1 Shanghai MicroPort Medical Group Co Ltd Pipeline Products &Ongoing Clinical Trials Overview952
  5.24 Tepha, Inc. Company Overview971
    5.24.1 Tepha, Inc. Pipeline Products &Ongoing Clinical Trials Overview972
  5.25 VasoTech Inc. Company Overview991
    5.25.1 VasoTech Inc. Pipeline Products &Ongoing Clinical Trials Overview992
  5.26 Xenogenics Corporation Company Overview1011
    5.26.1 Xenogenics Corporation Pipeline Products &Ongoing Clinical Trials Overview1014
6 Bioabsorbable Stents (BAS)- Recent Developments10523
  6.1 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer1051
  6.2 Sep 28, 2016: Nevada Heart And Vascular Center Announces Partnership With Desert Springs Hospital Offering First-Of-Its-Kind Naturally Dissolving Heart Stent For Patients With Coronary Artery Disease1051
  6.3 Aug 30, 2016: MPSC Announces 2016 Interim Results1061
  6.4 Aug 17, 2016: Fully Dissolving Stent Revolutionizes Heart Disease Treatment1071
  6.5 Aug 08, 2016: DMC Heart Hospital Offers First-Of-Its-Kind Naturally Dissolving Heart Stent To Patients With Coronary Artery Disease1081
  6.6 Aug 02, 2016: REVA Completes Submission of CE Mark Application1081
  6.7 Jul 29, 2016: Sutter Health advances cardiovascular service by offering first-of-its-kind fully dissolving heart stent in Bay Area and Sacramento1091
  6.8 Jul 29, 2016: REVA Medical: Quarter Ended 30 June 20161091
  6.9 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 20161102
  6.10 Jul 27, 2016: St. John Hospital &Medical Center Implants First Dissolving Heart Stent1121
  6.11 Jul 26, 2016: New Heart Device Trialed at Mercy Wins FDA Approval1121
  6.12 Jul 25, 2016: INTEGRIS Heart Hospital Implants First-of-its-kind Naturally Dissolving Heart Stent in Patient with Coronary Artery Disease1131
  6.13 Jul 14, 2016: St. Elizabeth s Medical Center Becomes First Hospital in New England to Implant Dissolvable Heart Stent1131
  6.14 Jul 14, 2016: Health Canada Approves Abbott's Absorb Bioresorbable Stent, The First Fully Dissolving Heart Stent1141
  6.15 Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors1151
  6.16 Jul 12, 2016: Good Samaritan Hospital First on the West Coast to Offer Naturally Dissolving Heart Stent to Patients with Coronary Artery Disease1151
  6.17 Jul 08, 2016: University Hospitals Case Medical Center cardiologists first to implant Abbott Absorb Stent in Midwest1161
  6.18 Jul 05, 2016: FDA approves first absorbable stent for coronary artery disease1171
  6.19 Jul 05, 2016: Arizona patient will receive first U.S.-approved fully dissolving heart stent1171
  6.20 Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation1181
  6.21 Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold1181
  6.22 Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold1191
  6.23 Jun 03, 2016: LEPUCARE established in India1191
  6.24 May 18, 2016: Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold in May1191
  6.25 May 18, 2016: REVA Sponsors Symposium at EuroPCR 20161201
  6.26 May 17, 2016: REVA Releases Positive Clinical Results for Fantom1201
  6.27 May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System DESolve CX at EuroPCR 20161212
  6.28 May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System AMITY at EuroPCR 20161231
  6.29 May 10, 2016: REVA to Present at EuroPCR 20161231
  6.30 Apr 01, 2016: MicroPort and Yizheng Municipal Government Establishes "Shanghai-Yizheng Healthcare Cooperation Project"1241
  6.31 Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device1241
  6.32 Mar 15, 2016: Abbott's Absorb, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee1241
  6.33 Feb 23, 2016: REVA Achieves Target Patient Enrollment in FANTOM II Trial1251
  6.34 Feb 10, 2016: REVA Announces Clinical Enrollment Progress and Anticipated $11.4 Million Cash Receipt1261
  6.35 Jan 19, 2016: REVA Hires Richard Kimes as SVP of Operations1262
7 Appendix1284
  7.1 Methodology1282
  7.2 About GlobalData1301
  7.3 Contact Us1301
  7.4 Disclaimer1311

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016" Nov 01, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Bioabsorbable-Stents-BAS-Medical-Devices-Pipeline-Assessment-2016-2085-23838>
  
APA:
GlobalData. (2016). Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016 Nov 01, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Bioabsorbable-Stents-BAS-Medical-Devices-Pipeline-Assessment-2016-2085-23838>
  
US$ 4,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.